Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
For patients unfamiliar with self-injection, this can initially feel daunting, but the technique is straightforward and is routinely taught by healthcare professionals
Quality and concentration vary by compounder
Under discussions tied to the Treat and Reduce Obesity Act, several major commercial insurers expanded GLP-1 obesity coverage in 2025-2026
As a novel GLP-1 receptor agonist, Retatrutide stands out by also targeting another third receptor to potentially amplify its impact on both weight reduction and blood sugar management
Semaglutide is a weight loss drug that targets the glucagon-like peptide-1 (GLP-1), sold by Novo Nordisk under the brand name Wegovy to treat people with obesity and under Ozempic to treat patients with both type 2 diabetes and obesity
US$ 28.31
US$ 25.49
US$ 29.65
US$ 21.47
